LUNDBECK, LLC

Lundbeck to acquire Longboard Pharmaceuticals for $2.6 billion in cash.

Neurocrine Biosciences' crinecerfont, targeting classic congenital adrenal hyperplasia (CAH), receives FDA Priority Review. If approved, it would be the first new CAH treatment in 70 years, offering a novel mechanism. CAH, caused by 21-hydroxylase gene mutations, affects hormone production in adrenal glands, with the US having the highest prevalence. Current treatments focus on managing symptoms, with EFMODY as the only approved drug in Europe. Emerging therapies like crinecerfont aim to normalize hormone levels and address the root cause of CAH.

Lundbeck presents TALISMAN and AMULET trial results on Multiple System Atrophy (MSA) at the International Congress of Parkinson's Disease and Movement Disorders. TALISMAN, a Chinese cohort study, aids in understanding MSA progression. AMULET, a phase II trial, shows potential efficacy of amlenetug (Lu AF82422) in slowing MSA progression, prompting a planned phase III trial in 2025.

Scientists at ETH Zurich found that an inexpensive antidepressant, vortioxetine, could be effective against glioblastomas, aggressive brain tumours with no cure. The drug, already on the market, can bypass the blood-brain barrier and showed promising results in tests on tumour tissue and mice. Researchers plan clinical trials to test its efficacy in humans.

Lundbeck starts phase I study with second-generation migraine drug Lu AG09222 for potential combination treatment in migraine prevention, as per Clinical Trials registration.